Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 42 min ago
Peer-reviewedCC BY-NCDrug Safety

Artificial Intelligence in Pharmacovigilance: Guiding Principles from the CIOMS Working Group XIV

55 more authors

60 listed; 67 in total.

8 affiliations
  1. 1Uppsala Monitoring Centre, Uppsala, Sweden. [email protected]
  2. 2European Medicines Agency, Amsterdam, Netherlands
  3. 3GSK, London, UK
  4. 4Johnson & Johnson, Horsham, PA, USA
  5. 5Biogen, Cambridge, MA, USA
  6. 6Council for International Organizations of Medical Sciences, Geneva, Switzerland
  7. 7Merck Healthcare, Darmstadt, Germany
  8. 8Johns Hopkins School of Medicine, Baltimore, MD, USA

Abstract

Artificial intelligence (AI) is increasingly being explored to support pharmacovigilance activities including processes involving individual case safety reports. These technologies may improve efficiency and enable new analytical capabilities, but they also raise important questions regarding the responsible use of these systems in contexts that directly support regulatory decision-making and patient safety. In response to these opportunities and challenges, the Council for International Organizations of Medical Sciences (CIOMS) set up Working Group XIV on Artificial Intelligence in Pharmacovigilance to establish and promote principles and guidance for this area. The resulting CIOMS report was published in December 2025 and presents seven guiding principles: risk-based approach, human oversight, validity and robustness, transparency, data privacy, fairness and equity, and governance and accountability. To maximise stakeholder awareness and understanding, this article provides an overview of the CIOMS XIV guidance and illustrates how these principles may be applied in practice through selected use cases. The report aims to support stakeholders in developing and deploying AI systems in a manner that maintains scientific rigor, transparency, and public trust while enabling innovation to support safe use of medicines worldwide.

Related

  1. Progress in pharmacovigilance research based on artificial intelligence and real-world data: a structured narrative review.
    Xuelin Sun, Dongfang Qian, Wenjing Zhao +3
    Journal of translational medicinePeer-reviewedCC BY-NC-NDFull textPharmacology & toxicologyEurope PMCPMC
  2. Artificial Intelligence-Enabled Pharmacovigilance for Neuropsychiatric Therapies: Advancing U.S. Drug Safety Surveillance and Regulatory Decision-Making
    Rebecca A Omachonu, Sandra A Uzuh, Kehinde Akinola +2
    CureusPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyPsychiatry & mental healthPMC
  3. Artificial intelligence in cardiology for non-experts: decoding key terms and understanding machine learning methodologies. A Scientific Statement of the ESC Working Group on e-Cardiology, the European Heart Rhythm Association (EHRA), the Association for Acute CardioVascular Care (ACVC), the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI), the European Association of Preventive Cardiology (EAPC), and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, the ESC Regulatory Affairs Committee, and the ESC Digital Cardiology and Artificial Intelligence Committee
    Raffaele De Lucia, Matthijs Cluitmans, Julia Ramírez +24
    European Heart Journal. Digital HealthPeer-reviewedCC BY-NC-ND 4.0Full textEpidemiology & public healthPMC
  4. CSF cytology: core principles, diagnostic pitfalls and emerging digital tools including artificial intelligence and telecytology.
    Sandra Nay, Franz Felix Konen, Franziska Bachhuber +29
    Acta neuropathologicaPeer-reviewedCC BYFull textPhysiologyEurope PMCPMC
  5. Guiding Principles for Pragmatic Randomized Trials of Tuberculosis Treatments
    Patrick P.J. Phillips, Samuel G. Schumacher, Aparna Anderson +20
    The Lancet. Infectious diseasesPeer-reviewedCC BY 4.0Full text1 citedInfectious diseasePMC
BibTeX
@article{noren2026artificial,
  title = {{Artificial Intelligence in Pharmacovigilance: Guiding Principles from the CIOMS Working Group XIV}},
  author = {G. Niklas Norén and Julie Durand and Vijay Kara and Elizabeth MacEntee Pileggi and Hua Carroll and Sanna Hill and Manfred Hauben and Taxiarchis Botsis and Lembit Rägo and CIOMS Working Group XIV and Russ Biagio Altman and Taxiarchis Botsis and Jean‐Michel Dogné and Justyna Amelio and Luisa Fernanda Barrios Martinez and Andrew Bate and Arvind Bellur and Adrian Berridge and Hua Carroll and Yauheniya Cherkas and Selin Cooper and Mariane Diniz and Douglas Domalik and Piero Francesco Franco and Julie Girod and Neal Grabowski and Manfred Hauben and Thomas Henn and Vijay Kara and Dieter Kempf and Kostadinos Kidos and Denny Lorenz and Elizabeth MacEntee Pileggi and Ravi Patel and John Reinhard Pietzsch and H.‐J. Römming and Walter Straus and James Whitehead and Brian Buch and Julie Durand and Kirsten Egebjerg Juul and Kendal Harrison and Satoko Hirokawa-Voorburg and Alexander Horst and Morten Jensen and Jesper Kjær and Benny Ling and Mônica da Luz Carvalho Soares and Yusuke Matsunaga and Dirk Mentzer and Manuela Messelhäußer and Flávia Moreira Cruz and Nicolas Perez and Irene Scholz and Thomas Stammschulte and Phil Tregunno and Roli Mathur and Eva-Lisa Meldau and G. Niklas Norén and Stephen Rosenfeld},
  journal = {Drug Safety},
  year = {2026},
  month = aug,
  doi = {10.1007/s40264-026-01708-z},
  url = {https://doi.org/10.1007/s40264-026-01708-z},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Artificial Intelligence in Pharmacovigilance: Guiding Principles from the CIOMS Working Group XIV
AU  - G. Niklas Norén
AU  - Julie Durand
AU  - Vijay Kara
AU  - Elizabeth MacEntee Pileggi
AU  - Hua Carroll
AU  - Sanna Hill
AU  - Manfred Hauben
AU  - Taxiarchis Botsis
AU  - Lembit Rägo
AU  - CIOMS Working Group XIV
AU  - Russ Biagio Altman
AU  - Taxiarchis Botsis
AU  - Jean‐Michel Dogné
AU  - Justyna Amelio
AU  - Luisa Fernanda Barrios Martinez
AU  - Andrew Bate
AU  - Arvind Bellur
AU  - Adrian Berridge
AU  - Hua Carroll
AU  - Yauheniya Cherkas
AU  - Selin Cooper
AU  - Mariane Diniz
AU  - Douglas Domalik
AU  - Piero Francesco Franco
AU  - Julie Girod
AU  - Neal Grabowski
AU  - Manfred Hauben
AU  - Thomas Henn
AU  - Vijay Kara
AU  - Dieter Kempf
AU  - Kostadinos Kidos
AU  - Denny Lorenz
AU  - Elizabeth MacEntee Pileggi
AU  - Ravi Patel
AU  - John Reinhard Pietzsch
AU  - H.‐J. Römming
AU  - Walter Straus
AU  - James Whitehead
AU  - Brian Buch
AU  - Julie Durand
AU  - Kirsten Egebjerg Juul
AU  - Kendal Harrison
AU  - Satoko Hirokawa-Voorburg
AU  - Alexander Horst
AU  - Morten Jensen
AU  - Jesper Kjær
AU  - Benny Ling
AU  - Mônica da Luz Carvalho Soares
AU  - Yusuke Matsunaga
AU  - Dirk Mentzer
AU  - Manuela Messelhäußer
AU  - Flávia Moreira Cruz
AU  - Nicolas Perez
AU  - Irene Scholz
AU  - Thomas Stammschulte
AU  - Phil Tregunno
AU  - Roli Mathur
AU  - Eva-Lisa Meldau
AU  - G. Niklas Norén
AU  - Stephen Rosenfeld
PY  - 2026
DA  - 2026/08/26
JO  - Drug Safety
DO  - 10.1007/s40264-026-01708-z
UR  - https://doi.org/10.1007/s40264-026-01708-z
AB  - Artificial intelligence (AI) is increasingly being explored to support pharmacovigilance activities including processes involving individual case safety reports. These technologies may improve efficiency and enable new analytical capabilities, but they also raise important questions regarding the responsible use of these systems in contexts that directly support regulatory decision-making and patient safety. In response to these opportunities and challenges, the Council for International Organizations of Medical Sciences (CIOMS) set up Working Group XIV on Artificial Intelligence in Pharmacovigilance to establish and promote principles and guidance for this area. The resulting CIOMS report was published in December 2025 and presents seven guiding principles: risk-based approach, human oversight, validity and robustness, transparency, data privacy, fairness and equity, and governance and accountability. To maximise stakeholder awareness and understanding, this article provides an overview of the CIOMS XIV guidance and illustrates how these principles may be applied in practice through selected use cases. The report aims to support stakeholders in developing and deploying AI systems in a manner that maintains scientific rigor, transparency, and public trust while enabling innovation to support safe use of medicines worldwide.
SN  - 0114-5916
SN  - 1179-1942
ER  -